Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer

This study will recruit 32 patients according to eligibility criteria and administer FTD/TPI (35 mg/m2) and intravenous ramucirumab (8 mg/kg). The primary endpoint will be the time to treatment failure. The secondary endpoints will include the overall survival time, progression-free survival time, overall response rate, disease control rate, relative dose intensity, and incidence of adverse events. The results will add new insights for improving the late-line treatment of advanced gastric cancer.PMID:38505718 | PMC:PMC10945229 | DOI:10.18999/nagjms.86.1.43

Source: Nagoya Journal of Medical Science - March 20, 2024 Category: International Medicine & Public Health Authors: Koki Nakanishi Chie Tanaka Mitsuro Kanda Kazushi Miyata Nozomu Machida Mitsuru Sakai Daisuke Kobayashi Hitoshi Teramoto Akiharu Ishiyama Bin Sato Takashi Oshima Masaki Kajikawa Hidenobu Matsushita Kiyoshi Ishigure Katsuya Yamashita Shinichi Fujitake Satos Source Type: research